To this end, we transplanted the whole BM cells from primary CML mice treated with vehicle, imatinib, a combination of imatinib and IRAK1/4 inhibitor and a combination of imatinib and anti-PD-L1 antibody into lethally irradiated recipient mice (Fig. 6a). This evidence concerns the gene IRAK1 and chronic myelogenous leukemia, BCR-ABL1 positive.